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Lifetime Risk from
Polyurethane Covered Breast
Implants
The recent article by Luu et al. (1) predicting
an excess lifetime riskfrom polyurethane cov-
ered breast implants of 1 in 400,000 is based
upon numerous questionable assumptions
and cannot go unchallenged. I have listed
below several of the more obvious problems
with this study and its conclusions.
The estimated dose of polyurethane was
too high. The authors use a weight of foam
in their dosage estimates of 4.87 grams, but
they do not reference the source for that fig-
ure. Presumably they meant two implants,
and not one as stated. From the best available
data, the Food and Drug Adminstration
(FDA) has previously used the figure of 1.35
g of foam per implant, or 2.7 g for two
implants (2). Even with two implants, the
polyurethane exposure is almost half of that
estimated by the authors.
Polyurethane oligomers were incorrectly
assumed to be 2,4-toluenediamine (2,4-
TDA). In one part ofthe study, 14C- labeled
foam was implanted subcutaneously in rats
(no information about where or how was
provided) at a dose of80 mg/kg body weight
(bw), and counts were measured in urine and
feces for up to 56 days. The authors appeared
to assume that any radioactive breakdown
products ofpolyurethane were 2,4-TDA and
not oligomers or metabolites. Because there is
no evidence that polyurethane oligomers are
mutagenic or carcinogenic, this difference is
ofcritical importance.
Implanted polyurethane in doses up to
267 mg/kg bw did not form DNA adducts in
a model where adducts could be demonstrat-
ed from 2,4-TDA (3). It has clearly been
shown that 2,4-TDA is artifactually created
from oligomers in urine during the extraction
process (4,5). Luu et al. (1) were unable to
measure any quantity of 2,4-TDA in blood
or urine after polyurethane implantation, yet
they graphically plotted and described data
(see Tables 3 and 4 in their paper) and calcu-
lated a risk assessment as if they had. There
was no mention of any evidence (or lack
thereof) of polyurethane-induced neoplasia
in this study, either grossly or histologically.
There were apparently no controls in this or
any other part ofthe study.
An inappropriate scaling factor was used.
The authors used a scaling factor of 45 in
their extrapolation of rat doses to humans,
based on an article by Ramsay and Anderson
(6), which reported styrene exposure by
inhalation in a rat model. Inhalation studies
must take into account many factors, such as
alveolar surface area, that are not relevant to
this discussion. Using the scaling factor creat-
ed for an inhalational model is not acceptable
for an injection or implantation model. Ifone
uses the estimated weight ratio of58 kg for a
human female (as used by Luu) and 0.25 kg
for the rat, the conversion factor is 232 and
not 45. The authors by this error alone have
overestimated the dose bya factor offive.
Previous risk assessments, polyurethane
studies in both animals and humans, and rel-
evant epidemiology were not considered in
the risk analysis. It was surprising that the
authors referenced as allegedly showing "a
potential health risk " the prior risk assess-
ment performed by the FDA, which estimat-
ed a lifetime cancer risk from two implants of
5 in 10 million (2). This FDA risk assess-
ment used the same potency factor [0.21
(mg/kg/day)'1 and degradation rate (88 ng/g
foam/day) as that of Luu et al. It assigned
variables that would overestimate the risk, as
compared to Luu who included a 35-year
exposure time (vs. 10 years) and a patient
weight of 50 kg (vs. 58 kg). The amount of
foam estimated was less in the FDA study, as
noted above. A separate calculation was per-
formed to determine the risk ifall ofthe 2,4-
TDA that could possibly be released from
two implants actually was. The FDA con-
cluded that "the study showed that the risk of
cancer from TDA released by polyurethane
breast implants is negligible. FDA estimates
it is unlikely that exposure to TDAwill cause
cancer in even one ofthe women with these
implants. The health riskconnected with sur-
gical removal of the implants is far greater
than the riskofdeveloping cancer." (7).
Another recently published risk assess-
ment (5) and the report of a Canadian
Medical Association Expert Panel (8) are
both in agreement with the FDA. While it is
acknowledged that Luu et al. (1) used a phys-
iologically based pharmacokinetic (PBPK)
model that is different from the others, it cre-
ates the appearance ofa crucial bias when the
major works of others are not recognized in
the discussion, and assumptions are made
that clearly overestimate a possible dose. This
negates whatever advantage the PBPK model
might provide.
Luu et al. (1) did not mention any
polyurethane implantation studies in animals
showing no chemical carcinogenesis (9-11),
clinical studies in humans demonstrating no
cancers (12-14), or epidemiologic studies
showing no increased risk of cancer from
exposure to 2,4-TDA-containing hair dyes
(15-17) or in polyurethane foam manufac-
turing plant workers (18-20). In attempting
to determine if2,4-TDA is a human carcino-
gen, and if so, at what dose, it would seem
important to consider these published stud-
ies. Only a few ofthe many articles on these
subjects are referenced in this letter.
The author's calculated theoretical risk is
not reliable. The primary conclusion
remains, as Luu et al. (1) so stated, that
"there is no data available at this time to
show a cause and effect relationship between
the use of this PU foam and production of
cancer in humans...." Their calculated risk of
1 in 400,000 would not reliably predict a sin-
gle neoplasm among the 100,000-200,000
women with polyurethane covered breast
implants. The fact remains that polyurethane
and 2,4-TDA are toxicologically distinct and
cannot scientifically be considered equiva-
lent. To avoid the groundless fear that this
paper might produce, patients with
polyurethane covered breast implants and
their doctors need to know that the risk
assessment of Luu et al. (1) is a theoretical
maximum risk based on assumptions that
greatly overestimate the dose, and that the
actual risk is far more likely to be null.
Kenneth Kulig
University ofColorado Health Sciences Center
ToxicologyAssociates
Denver, Colorado
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Response
In his comments on our paper, Kulig states
that "the estimated dose ofpolyurethane was
too high." The polyurethane foam mass
(4.87 g) used in this study corresponds to the
mass offoam covering two implants of500 g
each. The 2.7 greferred by Kulig corresponds
to the mass offoam covering two implants of
250 geach.
Another criticism was that "polyurethane
oligomers were incorrectly assumed to be
2,4-toluenediamine (2,4-TDA)". We did not
assume that all the degradation products were
oligomers. We also did not use an implant
study to calibrate the model. The text and
data in Figure 2 of our paper was clearly
identified as an intravenous (iv) bolus of0.52
mg/kg of 2,4-TDA. Obviously, this would
result in serum concentrations above the
detection limits, so that the model could be
calibrated. We never claimed that the data in
our Figure 2 was from an implant or that the
implant degradation product, 2,4-TDA,
could be detected in serum. This iv bolus
data of pure 2,4-TDA was used initially to
calibrate the PBPK model. Subsequently, the
PBPK model was used to simulate routes of
administration in the rat and in rat (0.021 g)
and human (4.872 g) implants in our Table
2. Table 3 in our paper shows a list ofmetab-
olism and excretion parameters, and not plas-
ma or urinary levels of2,4-TDA as indicated
in Kulig's comments. In Figure 3, we plotted
2,4-TDA serum concentrations of the simu-
lated low-dose rat iv bolus, feeding, and
implant cases, and not, urinary 14C 2,4-TDA
as Kulig claimed in his comments. The 14C
data were used only to validate the excretion
of2,4-TDA in rats.
We did not use an inappropriate scaling
factor. Metabolism has been clearly shown to
scale with the 0.7 power of the body weight
(1). Thus, the scaling factor is (58/0.25)0.7 =
(232)07 = 45. This has nothing to do with
the use of an inhalation route. This factor
applies to the forward rate constant for
metabolism in the liver.
Kulig stated that "previous risk assess-
ments, polyurethane studies in animals and
humans, and relevant epidemiology were not
considered in the risk analysis." First, it is
important to understand that the polyure-
thane foam breast implant has been voluntar-
ily withdrawn from the commercial market
since 17 April 1991. It is beyond the scope of
our paper to provide all the clinical evidence
to inform physicians or calm patients fears
with these implants. The purpose of this
paper was to use a novel approach, the PBPK
model, to predict the kinetics of chemicals
and extrapolate between different routes of
administration from animals to humans.
Kulig states that we used variables to inflate
the risk estimate. This is not correct. The
variables used in the risk estimate in this
study were chosen carefully to reflect avail-
able data from clinical reports. For example,
the lifetime of an implant was consistently
reported to be less than 10 years. This con-
clusion is based on "histological analysis of
retrieved explants and clinical observations"
as provided by the device manufacturer (2).
The predicted excess lifetime cancer riskof
1 in 400,000 in thisstudyrepresents the upper
limit on risk, based on the results ofthe kinet-
ics of intravenouly administered 2,4-TDA in
the rat extrapolated to humans using PBPK
modeling. Like many risk estimates, the esti-
mate in this paper is only as good as the
extrapolation of sometimes imperfect data
from animals to humans. It is, however, con-
sistent with the manufacturer's risk estimates
(2) and others previously conducted by the
FDA (3,4). In any case, the risk estimate does
not predict a significant increase in cancer
incidence for thosewomen implantedwith the
polyurethane foam-coated breastprostheses.
Hoan-MyDo Luu
Center for Devices and Radiological Health
Food and DrugAdministration
Rockville, Maryland
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Environmental Noise
Exposure
The article "Loud-but Not Yet Clear` in
the May issue of Environmental Health
Perspectives (J)discusses the subject of effects
of noise on health. This is the second article
in a short time that refers to this subject (2),
which we think is commendable.
Environmental noise exposure is an environ-
mental factor that seriously affects health and
well-being. This is also demonstrated by the
table presented in your article. This table
originated in the 1994 "Noise and Health"
report of the Health Council of the
Netherlands (3), as was duly mentioned in
the report of the Leicester Institute for
Environment and Health (4) to which your
article refers.
We would like to bring a related matter
to the attention of your readers. For an effi-
cient policy to reduce noise-induced health
effects outside the workplace, simple expo-
sure metrics are urgently required. This led
the Netherlands Minister ofthe Environment
to request the Health Council to recommend
such metrics to be used in national and in
European noise abatement policies. In
October 1997, the Health Council published
its report, titled "Assessing Noise Exposure
for Public Health Purposes," (5) which was
compiled by an international committee with
European and North-American membership.
This report recommended a method ofaggre-
gating noise exposure levels from different
sources with different qualities, taking into
account the exposure time of the day. The
resulting two metrics are thought to have
unambiguous relationships with noise annoy-
ance and with waking during the night. The
proposed metrics, the environmental expo-
sure level (EEL) and environmental night-
time exposure level (ENEL), are the adjusted
day-evening-night equivalent sound level
(LAeq,den) and the adjusted night-time equiva-
lent sound level (LAeq23 07h), respectively. As
already indicated, the adjustments pertain to
the source of the noise (mainly road traffic,
rail traffic, air traffic, industrial sources), the
nature of the noise (tonal, impulsive, indus-
trial components) and the exposure time of
the day (day: 700-1900 hr; evening:
1900-2300 hr; night: 2300-700 hr), as these
factors are known to modify the relationship
between the equivalent sound level and the
extent ofnoise-induced annoyance and sleep
disturbance. Most adjustment factors were
based on an evaluation by the committee ofa
comprehensive analysis of original data of
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